- Open Access
Unlocking HIV-1 Env: implications for antibody attack
© The Author(s) 2017
- Received: 9 March 2017
- Accepted: 11 August 2017
- Published: 12 September 2017
Collective evidence supporting a role of Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) in controlling HIV-1 transmission and disease progression emerged in the last few years. Non-neutralizing antibodies (nnAbs) recognizing conserved CD4-induced epitopes on Env and able to mediate potent ADCC against HIV-1-infected cells exposing Env in its CD4-bound conformation have been shown to be present in some RV144 vaccinees and most HIV-1-infected individuals. HIV-1 evolved sophisticated strategies to decrease exposure of this Env conformation by downregulating CD4 and by limiting the overall amount of cell-surface Env. In this review, we will summarize our contribution to this rapidly evolving field, discuss how structural properties of HIV-1 Env might have contributed to the modest efficacy of the RV144 trial and how we recently used this knowledge to develop new strategies aimed at sensitizing HIV-1-infected cells to ADCC mediated by easy to elicit nnAbs.
Neutralizing antibodies (NAbs) are generally central components of a protective vaccine-induced immune response. While design of immunogens able to elicit broadly reactive Nabs (bNAbs) remains a major goal of HIV-1 vaccine development, no HIV-1 vaccine candidate has fulfilled this goal . To date, only one anti-HIV-1 vaccine trial, the RV144 trial conducted in Thailand, presented a modest (31.2%) efficacy in preventing HIV-1 infection . Rather than bNAbs or CD8+ T cell response, protection was associated with the presence of anti-Env ADCC-mediating Abs in a subset of individuals with low plasma anti-Env IgA titer . Accordingly, non-neutralizing antibodies (nnAbs) with potent ADCC activity were isolated from some RV144 vaccinees . These findings suggested that ADCC-mediating Abs may have contributed to the partial protection observed in the RV144 trial and renewed interest in the mechanisms of recognition of these antibodies.
Besides being exposed at the surface of viral particles, the Env trimer represents the only virus-specific target at the surface of infected cells. We showed that interaction of Env with the viral receptor CD4 at the surface of the same HIV-1-infected cell is critical for the exposure of Env epitopes targeted by ADCC-mediating Abs . Strikingly, we demonstrated that multiple Abs with potent ADCC activity, including those isolated from RV144 vaccinees, preferentially target infected cells exposing Env in its CD4-bound conformation. Importantly, we observed that these antibodies are not uncommon since we observed that sera from a large number of HIV-1-infected individuals, at different stages of disease progression, contain a high prevalence of Abs that recognizes CD4-induced (CD4i) Env epitopes able to mediate ADCC responses . We further characterized the specificity of these Abs for their ability to mediate ADCC and found that anti-cluster A Abs, which recognize layer 1 and 2 of the gp120 inner domain, have a unique ability to eliminate infected cells exposing Env in its CD4-bound conformation [7, 8]. These nnAbs recognize transitional epitopes located in the inner domain of the gp120 subunit that are normally buried in the unbound Env trimer. These epitopes are commonly detected by Abs present in sera from HIV-1-infected individuals [6, 7, 9]. Accordingly, we demonstrated that a highly conserved tryptophan at position 69 of the gp120 inner domain, which plays a crucial role for Env trimer stability and its ability to transition to the CD4-bound conformation, is also critical for ADCC responses mediated by anti-cluster A Abs and HIV+ sera .
In addition to Vpu and Nef action, structural features of HIV-1 Env also influence the sensitivity of HIV-1 to ADCC. The Phe43 cavity, located at the interface of the inner and outer domains of gp120, allows the engagement with CD4 via its Phe43 residue  and modulates the propensity of Env that sample the CD4-bound conformation . Substitution of the well-conserved group M serine at position 375 by a larger residue such as tryptophan or histidine was found to fill the Phe43 cavity and result in the spontaneous sampling of a conformation closer to the CD4-bound state . Accordingly, we showed that filling this cavity with a histidine or tryptophan residue increased the susceptibility of HIV-1-infected cells to ADCC  (Fig. 1c). Surprisingly, while residue S375 is well-conserved among group M HIV-1 isolates, the predominant CRF01_AE strain in Thailand where the RV144 trial took place has a naturally-occurring histidine at this position (H375). Interestingly, H375 was recently shown to be important for CD4 binding in this strain  and its substitution by a serine (H375S) substantially reduces ADCC against CRF01_AE-infected cells mediated by Abs isolated from RV144 vaccinees . While a functional coevolution between the Phe43 cavity and the gp120 inner domain layers appears to compensate for the presence of H375 in CRF01_AE Envs , our results raise the intriguing possibility that this unique H375 polymorphism present in the circulating strains in Thailand might have contributed to the efficacy of the RV144 trial by naturally exposing CD4i ADCC-mediating epitopes. Although our results suggest that H375 might represent a point of vulnerability for the virus in vaccine settings, they do not necessarily imply that viral strains carrying the H375 polymorphism would be better controlled once the infection has been established. Supporting this, a recent study showed that filing the Phe43 cavity by residue 375 substitutions in simian-human immunodeficiency viruses (SHIV) enhanced viral replication in rhesus macaques .
The majority of circulating HIV-1 strains worldwide encodes functional Vpu and Nef proteins and express Env with “empty” Phe43 cavities (S375), which limit exposure of epitopes recognized by CD4i ADCC-mediating antibodies. Interestingly, we recently described a new strategy to overcome these protective mechanisms and sensitize HIV-1-infected cells to ADCC by modulating Env conformation using small CD4-mimetic compounds (CD4mc) . These CD4mc engage gp120 within the Phe43 cavity and can induce thermodynamic changes in the Env trimer similar to those observed upon binding by soluble CD4 . Using these CD4mc, we were able to force Env present at the surface of infected cells to sample the CD4-bound conformation and enhance recognition of infected cells by sera, breast milk and cervicovaginal fluids from HIV-1-infected subjects . This approach not only efficiently sensitized cells infected with full-length HIV-1 primary isolates to ADCC mediated by these biological fluids but it also sensitized endogenously infected ex vivo-amplified primary CD4+ T cells to ADCC mediated by autologous sera and autologous effector cells . We rationalized that the effect of CD4mc on ADCC could be influenced by the amount of Env present at the surface of infected cells where only limited amounts of Env are exposed due to efficient Vpu-mediated BST-2 downregulation [5, 10, 11]. Accordingly, we recently found that BST-2 expression, and its sensitivity to Vpu down modulation, dictate the ability of CD4mc to sensitize HIV-1-infected cells to ADCC by modulating the amount of Env able to engage CD4mc . Interestingly, we found that BST-2 upregulation by IFN-α, IFN-β or IL-27 induces Env accumulation at the cell surface and boosts the ability of CD4mc to sensitize HIV-1-infected cells to ADCC mediated by sera from HIV-1-infected individuals. These results suggest that combination of type 1 IFNs or IL-27 with CD4mc, might represent an attractive approach to target and eliminate HIV-1-infected cells through ADCC (Fig. 1d).
We recently characterized the different steps involved in the exposure of ADCC-mediating anti-cluster A epitopes and showed that it requires a sequential opening of the Env trimer . We found that CD4mc synergize with co-receptor binding site (CoRBS) Abs present in HIV+ sera to efficiently expose anti-cluster A epitopes and sensitize HIV-1-infected cells to ADCC. These findings helped to better define the specific Abs that could contribute to eliminate HIV-1-infected cells by ADCC and also provided crucial information for the design of immunogens aimed at generating an efficient ADCC response. Interestingly, both CoRBS and anti-cluster A Abs recognize highly-conserved Env epitopes and therefore such combination of nnAbs might represent a broad and potent approach to unlock HIV-1 Env and sensitize HIV-1-infected cells to ADCC.
Recent studies identified different bNAbs that can also mediate ADCC responses [11, 21, 22]. However, elicitation of potent bNAb is relatively rare and occurs after several years of infection . Moreover, elicitation of bNAbs by immunization remains an important challenge, since to date, no immunogen has induced bNAb responses that match those elicited during natural infection. In contrast, CD4i nnAbs are easy to elicit, commonly detected in HIV-1-infected individuals and mediate broad and potent ADCC responses when Env is exposed in its CD4-bound conformation. While vaccine trials in non-human primate (NHP) using various Env immunogens were unable to elicit bNAbs so far, sera from vaccinated NHP using different Env-based immunogens could easily neutralize HIV-1 in the presence of CD4mc. Thus, proving that CD4mc can sensitize HIV-1 Env to neutralization by easy-to-elicit CD4i Abs . Moreover, the same strategy resulted in efficient ADCC elimination of HIV-1-infected cells through ADCC responses . Altogether, these data suggest that combining Env-based immunogens with a small-molecule CD4mc, administered orally or in a microbicide formulation, might be useful as a prophylactic strategy against HIV-1 transmission.
All the elements required to eliminate HIV-1-infected cells by ADCC are already present in HIV-1-infected individuals. However, HIV-1 evolved multiple mechanisms to protect virus-producing cells from ADCC by reducing Env-CD4 complexes. Importantly, by enhancing both neutralization and ADCC activity of nnAbs, naturally present during HIV-1 infection or elicited upon immunization, CD4mc hold the promise of therapeutic utility in preventing and controlling HIV-1-infection.
JR, SD and AF wrote this review. All authors read and approved the final manuscript.
The authors thank Tanya Merke Epp, Deborah Douglas and the Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating Office (ACO) from the International Centre for Infectious Diseases (ICID) for organizing a CHVI vaccine meeting in Ottawa.
The authors declare that they have no competing interests.
Availability of data and materials
Consent for publication
Ethics approval and consent to participate
This work was supported by a CIHR foundation grant #352417 to A.F. A.F. is the recipient of a Canada Research Chair on Retroviral Entry. J.R. is the recipient of a CIHR Fellowship Award #135349. S.D. is the recipient of a CRCHUM postdoctoral fellowship.
Our funding sources had no role in data collection, analysis or interpretation, and were not involved in the writing of this manuscript.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Stephenson KE, D’Couto HT, Barouch DH. New concepts in HIV-1 vaccine development. Curr Opin Immunol. 2016;41:39–46.View ArticlePubMedPubMed CentralGoogle Scholar
- Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209–20.View ArticlePubMedGoogle Scholar
- Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275–86.View ArticlePubMedPubMed CentralGoogle Scholar
- Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM, et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol. 2012;86(21):11521–32.View ArticlePubMedPubMed CentralGoogle Scholar
- Veillette M, Desormeaux A, Medjahed H, Gharsallah NE, Coutu M, Baalwa J, Guan Y, Lewis G, Ferrari G, Hahn BH, et al. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J Virol. 2014;88(5):2633–44.View ArticlePubMedPubMed CentralGoogle Scholar
- Veillette M, Coutu M, Richard J, Batraville LA, Dagher O, Bernard N, Tremblay C, Kaufmann DE, Roger M, Finzi A. The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals. J Virol. 2015;89(1):545–51.View ArticlePubMedGoogle Scholar
- Ding S, Veillette M, Coutu M, Prevost J, Scharf L, Bjorkman PJ, Ferrari G, Robinson JE, Sturzel C, Hahn BH, et al. A highly conserved residue of the HIV-1 gp120 inner domain is important for antibody-dependent cellular cytotoxicity responses mediated by anti-cluster a antibodies. J Virol. 2015;90(4):2127–34.View ArticlePubMedGoogle Scholar
- Veillette M, Richard J, Pazgier M, Lewis GK, Parsons MS, Finzi A. Role of HIV-1 envelope glycoproteins conformation and accessory proteins on ADCC responses. Curr HIV Res. 2016;14(1):9–23.View ArticlePubMedGoogle Scholar
- Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, Freel S, Moody MA, Alam SM, Tomaras GD, Ochsenbauer C, et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol. 2011;85(14):7029–36.View ArticlePubMedPubMed CentralGoogle Scholar
- Alvarez RA, Hamlin RE, Monroe A, Moldt B, Hotta MT, Rodriguez Caprio G, Fierer DS, Simon V, Chen BK. HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. J Virol. 2014;88(11):6031–46.View ArticlePubMedPubMed CentralGoogle Scholar
- Arias JF, Heyer LN, von Bredow B, Weisgrau KL, Moldt B, Burton DR, Rakasz EG, Evans DT. Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. Proc Natl Acad Sci USA. 2014;111(17):6425–30.View ArticlePubMedPubMed CentralGoogle Scholar
- Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998;393(6686):648–59.View ArticlePubMedGoogle Scholar
- Xiang SH, Kwong PD, Gupta R, Rizzuto CD, Casper DJ, Wyatt R, Wang L, Hendrickson WA, Doyle ML, Sodroski J. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol. 2002;76(19):9888–99.View ArticlePubMedPubMed CentralGoogle Scholar
- Prevost J, Zoubchenok D, Richard J, Veillette M, Pacheco B, Coutu M, Brassard N, Parsons MS, Ruxrungtham K, Bunupuradah T, et al. Influence of the envelope Gp120 Phe 43 cavity on HIV-1 sensitivity to ADCC responses. J Virol. 2017;91:e02452.View ArticlePubMedGoogle Scholar
- Zoubchenok D, Veillette M, Prevost J, Sanders-Buell E, Wagh K, Korber B, Chenine AL, Finzi A. Histidine 375 modulates CD4 binding in HIV-1 CRF01_AE envelope glycoproteins. J Virol. 2017;91(4):e02151.View ArticlePubMedPubMed CentralGoogle Scholar
- Li H, Wang S, Kong R, Ding W, Lee FH, Parker Z, Kim E, Learn GH, Hahn P, Policicchio B, et al. Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc Natl Acad Sci USA. 2016;113(24):E3413–22.View ArticlePubMedPubMed CentralGoogle Scholar
- Richard J, Veillette M, Brassard N, Iyer SS, Roger M, Martin L, Pazgier M, Schon A, Freire E, Routy JP, et al. CD4 mimetics sensitize HIV-1-infected cells to ADCC. Proc Natl Acad Sci USA. 2015;112(20):E2687–94.View ArticlePubMedPubMed CentralGoogle Scholar
- Schon A, Madani N, Klein JC, Hubicki A, Ng D, Yang X, Smith AB 3rd, Sodroski J, Freire E. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry. 2006;45(36):10973–80.View ArticlePubMedPubMed CentralGoogle Scholar
- Richard J, Prevost J, von Bredow B, Ding S, Brassard N, Medjahed H, Coutu M, Melillo B, Bibollet-Ruche F, Hahn BH, et al. BST-2 expression modulates small CD4 mimetic sensitization of HIV-1-infected cells to ADCC. J Virol. 2017;91:e00219.View ArticlePubMedGoogle Scholar
- Richard J, Pacheco B, Gohain N, Veillette M, Ding S, Alsahafi N, Tolbert WD, Prevost J, Chapleau JP, Coutu M, et al. Co-receptor binding site antibodies enable CD4-mimetics to expose conserved anti-cluster A ADCC epitopes on HIV-1 envelope glycoproteins. EBioMedicine. 2016;12:208–18.View ArticlePubMedPubMed CentralGoogle Scholar
- Bruel T, Guivel-Benhassine F, Amraoui S, Malbec M, Richard L, Bourdic K, Donahue DA, Lorin V, Casartelli N, Noel N, et al. Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat Commun. 2016;7:10844.View ArticlePubMedPubMed CentralGoogle Scholar
- von Bredow B, Arias JF, Heyer LN, Moldt B, Le K, Robinson JE, Zolla-Pazner S, Burton DR, Evans DT. Comparison of antibody-dependent cell-mediated cytotoxicity and virus neutralization by HIV-1 env-specific monoclonal antibodies. J Virol. 2016;90(13):6127–39.View ArticleGoogle Scholar
- Burton DR, Hangartner L. Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu Rev Immunol. 2016;34:635–59.View ArticlePubMedGoogle Scholar
- Madani N, Princiotto AM, Easterhoff D, Bradley T, Luo K, Williams WB, Liao HX, Moody MA, Phad GE, Vazquez Bernat N, et al. Antibodies elicited by multiple envelope glycoprotein immunogens in primates neutralize primary human immunodeficiency viruses (HIV-1) sensitized by CD4-mimetic compounds. J Virol. 2016;90(10):5031–46.View ArticlePubMedPubMed CentralGoogle Scholar
- Ding S, Verly MM, Princiotto A, Melillo B, Moody AM, Bradley T, Easterhoff D, Roger M, Hahn BH, Madani N, et al. Small-molecule CD4 mimetics sensitize HIV-1-infected cells to antibody-dependent cellular cytotoxicity by antibodies elicited by multiple envelope glycoprotein immunogens in nonhuman primates. AIDS Res Hum Retroviruses. 2016;33(5):428–31.View ArticlePubMedGoogle Scholar